IMSVISUAL is holding its annual symposium in conjunction with the ACTRIMS Forum 2023 in San Diego, California on Saturday, February 25 from 12:30 – 1:30 PM PST. Please see the symposium schedule below. Click here to register for the ACTRIMS Forum 2023 and attend our session live.
IMSVISUAL will hold a virtual symposium in conjunction with the ACTRIMS Forum 2021, which will take place virtually February 25-27, 2021. The IMSVISUAL Symposium is available to all registrants of the ACTRIMS Forum 2021
Symposium Chairs: E. Ann Yeh, The Hospital for Sick Children and Philipp Albrecht, University Hospital Düsseldorf
Six Months Results from the TONE Trial (Treatment of Optic Neuritis with Erythropoietin) in the Context of Visual Pathway Neuroprotection
Wolf Lagrèze, Universitätsklinikum Freiburg
Visual Outcome Metrics in MS: What are the Opportunities?
Heather Moss, Stanford University
Socioeconomic Disparity Correlates with Faster Inner Retinal Layer Thickness in Multiple Sclerosis
Elena Vasileiou, Johns Hopkins University School of Medicine
Identification of Optical Coherence Tomography Phenotypes and their Relationship with Patient Outcomes in Youth with Demyelinating Syndromes: Preliminary Results of an Unsupervised Machine Learning Analysis
Beyza Cifti-Kavakioglu, The Hospital for Sick Children
Neuroprotective Effects of the Sphingosine 1 Phosphate Receptor 1/5 Modulator RP-101074 on Retinal Neurodegeneration and Visual Function in Light-Induced Photoreceptor Loss
Christina Hecker, UKD
Thursday, February 27, 2020, 11:15 am – 1:45 pm
Palm Beach County Convention Center, Grand Ballroom
This symposium is included in your ACTRIMS Forum 2020 registration. You must be registered for the Forum to attend this symposium.
|Part 1: Chaired by Jiwon Oh, University of Toronto; Alex Brandt, Charité-Universitätsmedizin Berlin|
|11:15am-11:35am||Harmonizing Neuroimaging Data in Collaborative Networks|
Taki Shinohara, University of Pennsylvania
|11:35am-11:50am||Visual Outcomes in Pediatric Demyelinating Disorders|
Ann Yeh, The Hospital for Sick Children
|11:50am-12:05pm||Retinal Ganglion Cell Layer Thickness for Risk Stratification in Early Multiple Sclerosis|
Hanna Zimmermann, Charité-Universitätsmedizin Berlin
|12:05pm-12:15pm||A New MRI Method for Visualizing Subpial Cortical Lesions at 3 Tesla|
Erin Beck, National Institute of Neurological Disorders and Stroke, National Institutes of Health
|Part 2: Chaired by Shiv Saidha, Johns Hopkins University; Eric Klawiter, Massachusetts General Hospital|
|12:45pm-1:00pm||Genetic Predictors of Visual Dysfunction in People with Multiple Sclerosis|
Kathryn Fitzgerald, Johns Hopkins University
|1:00pm-1:20pm||Imaging Correlates of Axonal Damage in MS|
Susie Huang, Massachusetts General Hospital, Harvard Medical School
|1:20pm-1:35pm||VISIONARY-MS: A Phase 2 clinical trial of catalytic gold nanocrystals, CNM-Au8, for the treatment of chronic optic neuropathy |
Robert Glanzman, Clene Nanomedicine, Inc.
|1:35pm-1:45pm||Functional Connectivity Predicts MS Patients' Impairment Using An Ensemble Model Applied With A Machine Learning Approach|
Ceren Tozlu, Weill Cornell Medicine
Please save the date for the following IMSVISUAL Events, taking place in conjunction with the ACTRIMS Forum 2020 in West Palm Beach, February 27-29, 2020.
- IMSVISUAL Member Meeting: 7:30-9:00am, Thursday, February 27
- Joint NAIMS-IMSVISUAL Symposium: 11:15am-1:45pm, Thursday, February 27
Thursday, September 12, 2019, 17:00
Meeting Room B9, Stockholmsmässan
ECTRIMS Congress Venue
|17:00||Welcome and Proceedings
F. Paul, Berlin
|17:15||Results of the OCTIMS study
F. Paul, Berlin
|17:30||OCT in experimental MS models
P. Albrecht, Düsseldorf
|17:45||Vision investigator race
4 brief presentations by junior researchers
|18:45||Miscellaneous and Farewell|
Snacks and beverages will be provided.
The number of participants is limited to 50 pax. Please RSVP until September 5th, 2019, by using the online registration form.
It is our pleasure to invite you to our IMSVISUAL symposium at ACTRIMS (being held in San Diego, California, February 1 – 3), to discuss updates on vision research in multiple sclerosis and related disorders. For the second consecutive year we are fortunate to have secured ACTRIMS as our sponsor.
The symposium, integrated into the ACTRIMS program and CME accredited, will take place on Friday February 2nd from 7am – 8.15am. Please see below the confirmed agenda for talks/speakers during the session. This symposium/session is open to all attendees of the ACTRIMS 2018 forum.
I think this will be an exciting symposium with presentations from
several groups representing existing IMSVISUAL member sites from
around the world.
In addition to the IMSVISUAL symposium, there will also be a separate IMSVISUAL consortium board meeting. This will take place Thursday, February 1st from 10.45am – 12pm. Space for the board meeting is limited to 35 participants so we kindly ask that you register using the link below only if you plan to attend. There should be ample time for discussion and establishing future collaborations during the meeting. Light snacks will also be provided.
We look forward to seeing you all in Florida.
IMSVISUAL symposium ACTRIMS Friday February 2nd
Session Chairs: Shiv Saidha & Alexander Brandt
“Mechanisms of disease progression in MS. Lessons from the anterior visual pathway”
“Trials without all the tribulations: Using the Visual System as an outcome in MS”
“Complementing NMO Genetics to Visual Pathology”
“Alterations of retinal vessel structures during multiple sclerosis – new implications for disease monitoring”
“OCT and MS Disease Progression: The Good, The Bad, and the Ugly”
We welcome Dr. Axel Petzold as new member in the IMSVISUAL Board of Directors. Dr. Petzold graduated from the Medical University of Freiburg (Germany). He received his MD in Experimental Ophthalmology with Ted Sharpe (University of Freiburg) and his PhD in Biochemistry with Ed Thompson (University College London). He trained as a neurologist in France (Lyon), Germany (Munich) and the United Kingdom (London). He currently works as consultant neurologist at Moorfields Eye Hospital London UK, the UCL Institute of Neurology and the VU Medical Center Amsterdam. In his research he focusses on axonal degeneration mainly in multiple sclerosis and optic nerve disease but also other diseases and models.
Dr. Petzold follows Dr. Villoslada, who now works at Genentech as Senior Medical Director, Late Clinical Development Neurosciences. We wish Dr. Villoslada all the best at Genentech and thank him for his tremendous effort to found IMSVISUAL.
We also welcome Dr. Lisanne Balk as new member of the IMSVISUAL Working Committee. Dr. Balk is a clinical epidemiologist, currently working as a post-
Dear IMSVISUAL Members, Dear Colleagues,
It is our pleasure to invite you to our next IMSVISUAL Consortium meeting at ECTRIMS in Paris on Friday, October 27, from 5 to 8 p.m. Please see details on the meeting venue in the attached PDF. A meeting agenda will be circulated in the next few weeks. Please indicate your attendance by email to Maria Weinhold (firstname.lastname@example.org).
We encourage all IMSVISUAL members (in particular our younger colleagues) to briefly present ideas for future collaborative research projects within IMSVISUAL as well as recent own research. If you are interested in presenting your work, or would like to share ideas for future projects we suggest that you state this in your registration email and provide a short tentative title.
We are looking forward to seeing you in Paris.
Scientists from Berlin have developed an intravital multiphoton microscopy prototype for repeated retinal measurements in mice. Using this system, Bremer et al. investigated neuronal dysfunction in the retinal ganglion cell layer in an experimental autoimmune uveoretinitis model.
The results of the study have been published in Frontiers in Immunology on Dec 23rd 2016 and are available in full as open access.